Research Progress on the Mechanism of Hyperuricemic Nephropathy Based on Multi-omics Technique: A Review

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2024 Dec 20

PMID 39705438

Authors

Kaiqing Li

Xue Xia

Tong Fu

Yanchun Ma

Yingwei Wang

Mingming Fan

Songyan Wang

Guoli Xing

Ying Tong

Affiliations

Soon will be listed here.

Abstract

Hyperuricemic nephropathy is a metabolic disease in which renal uric acid deposition and excretion are impaired due to elevated levels of uric acid in the blood, leading to impaired renal tubule function and chronic renal disease. Hyperuricemic nephropathy is one of the important complications of hyperuricemia, which seriously affects the quality of life and prognosis of patients. The pathogenesis of hyperuricemic nephropathy involves a variety of factors, including: amino acid metabolism disorder, energy metabolism abnormality, increased nucleotide metabolism, lipid metabolism disorder and bile acid metabolism imbalance, REDOX process disorder, cell cycle and apoptosis imbalance, signal transduction and inflammatory response enhancement, and intestinal flora imbalance. In recent years, omics techniques such as metabolomics, transcriptomics and intestinal microecology have been used to reveal the metabolic, gene and microflora characteristics of hyperuricemic nephropathy from different levels, as well as their interactions and regulatory mechanisms. This paper reviews these studies, analyzes the existing problems and challenges, and puts forward future research directions and suggestions, aiming at providing new theoretical basis and practical guidance for the prevention and treatment of hyperuricemic nephropathy.

References

Wu X, You C . The biomarkers discovery of hyperuricemia and gout: proteomics and metabolomics. PeerJ. 2023; 11:e14554. PMC: 9828291. DOI: 10.7717/peerj.14554. View

Wen L, Yang H, Ma L, Fu P . The roles of NLRP3 inflammasome-mediated signaling pathways in hyperuricemic nephropathy. Mol Cell Biochem. 2021; 476(3):1377-1386. DOI: 10.1007/s11010-020-03997-z. View

Li X, Yan Z, Carlstrom M, Tian J, Zhang X, Zhang W . Mangiferin Ameliorates Hyperuricemic Nephropathy Which Is Associated With Downregulation of AQP2 and Increased Urinary Uric Acid Excretion. Front Pharmacol. 2020; 11:49. PMC: 7020245. DOI: 10.3389/fphar.2020.00049. View

Ren Q, Wang B, Guo F, Huang R, Tan Z, Ma L . Natural Flavonoid Pectolinarigenin Alleviated Hyperuricemic Nephropathy via Suppressing TGFβ/SMAD3 and JAK2/STAT3 Signaling Pathways. Front Pharmacol. 2022; 12:792139. PMC: 8829971. DOI: 10.3389/fphar.2021.792139. View

Valsaraj R, Singh A, Gangopadhyay K, Ghoshdastidar B, Goyal G, Batin M . Management of asymptomatic hyperuricemia: Integrated Diabetes & Endocrine Academy (IDEA) consensus statement. Diabetes Metab Syndr. 2020; 14(2):93-100. DOI: 10.1016/j.dsx.2020.01.007. View

Tan Y, Wang L, Gao J, Ma J, Yu H, Zhang Y . Multiomics Integrative Analysis for Discovering the Potential Mechanism of Dioscin against Hyperuricemia Mice. J Proteome Res. 2020; 20(1):645-660. DOI: 10.1021/acs.jproteome.0c00584. View

Czajkowska A, Kazmierczak-Siedlecka K, Jamiol-Milc D, Gutowska I, Skonieczna-Zydecka K . Gut microbiota and its metabolic potential. Eur Rev Med Pharmacol Sci. 2020; 24(24):12971-12977. DOI: 10.26355/eurrev_202012_24201. View

Li N, Amatjan M, He P, Wu M, Yan H, Shao X . Whole transcriptome expression profiles in kidney samples from rats with hyperuricaemic nephropathy. PLoS One. 2022; 17(12):e0276591. PMC: 9762607. DOI: 10.1371/journal.pone.0276591. View

Xu D, Lv Q, Wang X, Cui X, Zhao P, Yang X . Hyperuricemia is associated with impaired intestinal permeability in mice. Am J Physiol Gastrointest Liver Physiol. 2019; 317(4):G484-G492. DOI: 10.1152/ajpgi.00151.2019. View

10.

Li N, Amatjan M, He P, Zhang B, Mai X, Jiang Q . Integration of network pharmacology and intestinal flora to investigate the mechanism of action of Chinese herbal formula in attenuating adenine and ethambutol hydrochloride-induced hyperuricemic nephropathy in rats. Pharm Biol. 2022; 60(1):2338-2354. PMC: 9897651. DOI: 10.1080/13880209.2022.2147551. View

11.

Asseri A, Bakhsh T, Abuzahrah S, Ali S, Rather I . The gut dysbiosis-cancer axis: illuminating novel insights and implications for clinical practice. Front Pharmacol. 2023; 14:1208044. PMC: 10288883. DOI: 10.3389/fphar.2023.1208044. View

12.

Reynolds R, Irvin M, Bridges S, Kim H, Merriman T, Arnett D . Genetic correlations between traits associated with hyperuricemia, gout, and comorbidities. Eur J Hum Genet. 2021; 29(9):1438-1445. PMC: 8440599. DOI: 10.1038/s41431-021-00830-z. View

13.

Pan L, Han P, Ma S, Peng R, Wang C, Kong W . Abnormal metabolism of gut microbiota reveals the possible molecular mechanism of nephropathy induced by hyperuricemia. Acta Pharm Sin B. 2020; 10(2):249-261. PMC: 7016297. DOI: 10.1016/j.apsb.2019.10.007. View

14.

Guo Y, Li H, Liu Z, Li C, Chen Y, Jiang C . Impaired intestinal barrier function in a mouse model of hyperuricemia. Mol Med Rep. 2019; 20(4):3292-3300. PMC: 6755192. DOI: 10.3892/mmr.2019.10586. View

15.

Qin N, Qin M, Shi W, Kong L, Wang L, Xu G . Investigation of pathogenesis of hyperuricemia based on untargeted and targeted metabolomics. Sci Rep. 2022; 12(1):13980. PMC: 9386008. DOI: 10.1038/s41598-022-18361-y. View

16.

Zhang H, Xiu M, Li H, Li M, Xue X, He Y . Cadmium exposure dysregulates purine metabolism and homeostasis across the gut-liver axis in a mouse model. Ecotoxicol Environ Saf. 2023; 266:115587. DOI: 10.1016/j.ecoenv.2023.115587. View

17.

Dehlin M, Jacobsson L, Roddy E . Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020; 16(7):380-390. DOI: 10.1038/s41584-020-0441-1. View

18.

Wei X, Jia X, Liu R, Zhang S, Liu S, An J . Metabolic pathway analysis of hyperuricaemia patients with hyperlipidaemia based on high-throughput mass spectrometry: a case‒control study. Lipids Health Dis. 2022; 21(1):151. PMC: 9805114. DOI: 10.1186/s12944-022-01765-0. View

19.

Wang Y, Chen Y, Hsiao C, Pan M, Wang B, Chen Y . Induction of Autophagy by Pterostilbene Contributes to the Prevention of Renal Fibrosis via Attenuating NLRP3 Inflammasome Activation and Epithelial-Mesenchymal Transition. Front Cell Dev Biol. 2020; 8:436. PMC: 7283393. DOI: 10.3389/fcell.2020.00436. View

20.

Chen-Xu M, Yokose C, Rai S, Pillinger M, Choi H . Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016. Arthritis Rheumatol. 2019; 71(6):991-999. PMC: 6536335. DOI: 10.1002/art.40807. View